41 Canadian Experts Request Amendment to Schedule 1 of the Patent Act to include COVID-19 vaccines

On April 27th, a letter signed by 41 Canadian experts was sent to the Prime Minister of Canada, the Minister of Innovation, Science & Industry, and the Minister of Health. The letter requests the amendment of Schedule 1 of the… Continue Reading

Canada based Biolyse Pharma Seeks to Manufacture COVID-19 Vaccines for Low-Income Countries, may test Canada’s compulsory licensing for export law

On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading

Unredacted Pfizer contract with Dominican Republic, shows broad indemnity provisions for COVID-19 vaccine sales

On March 1, 2021, KEI obtained a copy of the binding term sheet between Pfizer/BioNTech and the Dominican Republic for the supply of their COVID-19 vaccine in the country. The document, requested via the freedom of information law in the… Continue Reading

KEI Letter to New WTO Director-General on COVID-19 Response

On March 1, 2021, Knowledge Ecology International (KEI) sent a letter to Dr. Ngozi Okonjo-Iweala, the new Director-General of the World Trade Organization (WTO) regarding the WTO’s COVID-19 response. In the letter, KEI urged Dr. Ngozi to fully step into… Continue Reading

Manufacturers of COVID-19 vaccines typically start delivering in under six months after tech transfer

Based on press releases and additional publicly-available information, KEI is building a dataset with a non-exhaustive list of deals that involve technology transfer and outsourcing of COVID-19 vaccines manufacturing. As of February 19, 2021, the dataset includes observations for over… Continue Reading

COVID-19 Vaccine Manufacturing Capacity

KEI has created a public listserve to discuss vaccine manufacturing scale up. (link) February 19, 2021: Roundtable on Pathways to Scale Up Manufacturing Capacity for COVID-19 Vaccines – 19. KEI has gathered data regarding vaccine manufacturing capacity in countries worldwide,… Continue Reading

Foundational mRNA patents are subject to the Bayh-Dole Act provisions

Katalin Karikó and Drew Weissman are often described as the pioneers of the mRNA discoveries that underpin the first COVID-19 vaccines. In 2005 both scientists published a paper reporting that a slightly tweaked version of mRNA that can be administered… Continue Reading

COVID-19 Contracts

United States of America Below are links to copies of the contracts entered into by the US government for technologies to combat the COVID-19 pandemic. KEI is updating this page as we gain access to more contracts, and less redacted… Continue Reading